These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24493873)

  • 1. Sulodexide and glycosaminoglycans in the progression of renal disease.
    Masola V; Zaza G; Gambaro G
    Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i74-i79. PubMed ID: 24493873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition.
    Masola V; Onisto M; Zaza G; Lupo A; Gambaro G
    J Transl Med; 2012 Oct; 10():213. PubMed ID: 23095131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies.
    Zilişteanu DS; Atasie T; Voiculescu M
    Rom J Intern Med; 2015; 53(2):161-9. PubMed ID: 26402986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats.
    Chen S; Fang Z; Zhu Z; Deng A; Liu J; Zhang C
    J Huazhong Univ Sci Technolog Med Sci; 2009 Dec; 29(6):715-9. PubMed ID: 20037813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients.
    Sulikowska B; Olejniczak H; Muszyńska M; Odrowaz-Sypniewska G; Gaddi A; Savini C; Cicero AF; Laghi L; Manitius J
    Am J Nephrol; 2006; 26(6):621-8. PubMed ID: 17191008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy.
    Bang K; Chin HJ; Chae DW; Joo KW; Kim YS; Kim S; Ju KD; Kim H; Ahn C; Oh KH
    Yonsei Med J; 2011 Jul; 52(4):588-94. PubMed ID: 21623600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J;
    Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review.
    Li R; Xing J; Mu X; Wang H; Zhang L; Zhao Y; Zhang Y
    Drug Des Devel Ther; 2015; 9():6275-83. PubMed ID: 26664049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulodexide: a renewed interest in this glycosaminoglycan.
    Lauver DA; Lucchesi BR
    Cardiovasc Drug Rev; 2006; 24(3-4):214-26. PubMed ID: 17214598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One year course of oral sulodexide in the management of diabetic nephropathy.
    Achour A; Kacem M; Dibej K; Skhiri H; Bouraoui S; El May M
    J Nephrol; 2005; 18(5):568-74. PubMed ID: 16299683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
    Lewis EJ; Lewis JB; Greene T; Hunsicker LG; Berl T; Pohl MA; de Zeeuw D; Heerspink HL; Rohde RD; Atkins RC; Reutens AT; Packham DK; Raz I;
    Am J Kidney Dis; 2011 Nov; 58(5):729-36. PubMed ID: 21872376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal protective effects of sulodexide in diabetic rats and its anti-oxidative mechanism].
    Shu J; Zeng LY; Lin KY; Mu PW; Zhang GC; Chen YM; Wang MM
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):778-80. PubMed ID: 19403420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats.
    Cha JJ; Kang YS; Hyun YY; Han SY; Jee YH; Han KH; Han JY; Cha DR
    Life Sci; 2013 Jun; 92(23):1118-24. PubMed ID: 23643633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulodexide in the treatment of chronic venous disease.
    Andreozzi GM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):73-81. PubMed ID: 22329592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide.
    Harenberg J
    Med Res Rev; 1998 Jan; 18(1):1-20. PubMed ID: 9436179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of sulodexide might be associated with inhibition of complement system in hepatitis B virus-associated membranous nephropathy: An inspiration from a pilot trial.
    Yang Y; Ma L; Wang C; Kong D; Wang Y; Mei C
    Eur J Intern Med; 2016 Jul; 32():96-104. PubMed ID: 27160380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide.
    Adiguzel C; Iqbal O; Hoppensteadt D; Jeske W; Cunanan J; Litinas E; He Zhu ; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):501-11. PubMed ID: 19703818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy of Sulodexide--a low-molecular heparin--in the therapy of diabetic nephropathy].
    Shestakova MV; Chugunova LA; Vorontsov AV; Dedov II
    Ter Arkh; 1997; 69(6):34-7. PubMed ID: 9297270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosaminoglycans and fucoidan have a protective effect on experimental glomerulonephritis.
    Buijsers B; Maciej-Hulme M; Jacobs M; Bebber MB; de Graaf M; Salmenov R; Parr N; Rabelink TJ; Nijenhuis T; van der Vlag J
    Front Mol Biosci; 2023; 10():1223972. PubMed ID: 37475889
    [No Abstract]   [Full Text] [Related]  

  • 20. Sulodexide for diabetic nephropathy: another one bites the dust.
    House AA; Weir MA
    Am J Kidney Dis; 2011 Nov; 58(5):692-4. PubMed ID: 22014634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.